IRIS
CORALLO, SALVATORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.454
AS - Asia 1.355
EU - Europa 768
SA - Sud America 208
Continente sconosciuto - Info sul continente non disponibili 106
AF - Africa 49
OC - Oceania 3
Totale 3.943
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.385
SG - Singapore 375
CN - Cina 337
IT - Italia 246
HK - Hong Kong 189
BD - Bangladesh 188
BR - Brasile 154
RU - Federazione Russa 149
VN - Vietnam 129
DE - Germania 107
FR - Francia 69
GB - Regno Unito 55
FI - Finlandia 35
IN - India 29
CA - Canada 28
PL - Polonia 23
MX - Messico 21
ZA - Sudafrica 21
AR - Argentina 19
AT - Austria 17
TR - Turchia 15
ES - Italia 14
IQ - Iraq 11
NL - Olanda 11
EC - Ecuador 10
PK - Pakistan 10
CR - Costa Rica 8
ID - Indonesia 8
JP - Giappone 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
CO - Colombia 7
MA - Marocco 7
MY - Malesia 7
SE - Svezia 7
VE - Venezuela 7
IE - Irlanda 6
IL - Israele 5
PH - Filippine 5
UZ - Uzbekistan 5
BA - Bosnia-Erzegovina 4
CL - Cile 4
KE - Kenya 4
LT - Lituania 4
TH - Thailandia 4
AO - Angola 3
AU - Australia 3
BE - Belgio 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
JM - Giamaica 3
JO - Giordania 3
NP - Nepal 3
PE - Perù 3
SA - Arabia Saudita 3
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
DZ - Algeria 2
ET - Etiopia 2
KZ - Kazakistan 2
LV - Lettonia 2
MD - Moldavia 2
MM - Myanmar 2
MN - Mongolia 2
PA - Panama 2
PY - Paraguay 2
RO - Romania 2
UA - Ucraina 2
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EE - Estonia 1
GR - Grecia 1
IR - Iran 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MT - Malta 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 3.837
Salva come PNG Salva come JPEG
Città #
San Jose 253
Hong Kong 183
Singapore 179
Dallas 173
Council Bluffs 149
Ashburn 141
Beijing 126
Los Angeles 60
Lauterbourg 49
Ho Chi Minh City 46
New York 45
Columbus 41
Buffalo 39
Santa Clara 39
Munich 34
Hanoi 33
Milan 33
Redondo Beach 31
Turku 28
Nuremberg 27
São Paulo 21
Warsaw 20
Moscow 19
Johannesburg 18
Orem 18
Rome 18
Falkenstein 16
Denver 13
Cergnago 11
Mexico City 11
Montreal 11
Atlanta 10
Boardman 10
Chicago 10
Da Nang 10
Düsseldorf 10
Frankfurt am Main 9
Houston 9
London 9
Brooklyn 8
Tokyo 8
Boston 7
Cagliari 7
Chennai 7
Florence 7
Helsinki 7
Phoenix 7
Stockholm 7
Dublin 6
Figino 6
Haiphong 6
Nova Milanese 6
Poplar 6
San Francisco 6
Seattle 6
The Dalles 6
Toronto 6
Vienna 6
Ankara 5
Belo Horizonte 5
Biên Hòa 5
Kuala Lumpur 5
Manchester 5
Medford 5
Naples 5
Pavia 5
Portsmouth 5
Rio de Janeiro 5
San José 5
Shanghai 5
Turin 5
Bangkok 4
Genoa 4
Hangzhou 4
Hyderabad 4
Oujda 4
Secaucus 4
Tashkent 4
Amman 3
Amsterdam 3
Bari 3
Brasília 3
Brussels 3
Bến Tre 3
Changsha 3
Charlotte 3
Delhi 3
Desio 3
Dubai 3
Guatemala City 3
Londrina 3
Nairobi 3
Orangeburg 3
Padua 3
Shijiazhuang 3
Tel Aviv 3
Tianjin 3
Vancouver 3
Zhoukou 3
Abu Dhabi 2
Totale 2.245
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 151
Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed pseudomyxoma peritonei 124
Development, Expansion, and Histological Characterization of Patient-Derived Liver Organoids for Drug Screening and Disease Modeling 121
Should we exclude patients with peritoneal carcinosis of colorectal origin and high PCI from CRS + HIPEC? 113
Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study 104
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer 100
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study 96
First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study 91
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study 88
Chemotherapy-induced changes in plasma amino acids and lipid oxidation of resected patients with colorectal cancer: a background for future studies 84
Pink-on-pink: hepatocellular carcinoma metastatic to oncocytic carcinoma of the thyroid 82
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial 80
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization 80
Vaccine hesitancy in patients with solid tumors: a cross-sectional single-center survey 76
HER2, HER3, and Mismatch Repair Protein Expression in Stage IV Small Bowel Adenocarcinoma: Results From a Multicenter Series 73
Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review 69
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer 68
Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features 67
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study 65
Adenomyoma/adenomyomatosis-associated mural intracholecystic neoplasms: analysis of clinico-pathologic, imaging, and molecular features of a consecutive case series 64
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation 64
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 64
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 63
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S 61
Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric cancer (mGC): The VERA study 61
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer 60
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study 58
Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification-A pooled analysis of TRIBE and TRIBE2 studies by GONO 58
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study 57
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase 57
Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality 57
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 57
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 54
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 53
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective 51
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 50
Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study 49
The Key Role of Patient Empowerment in the Future Management of Cancer-Related Malnutrition 47
Nutritional support management in resectable gastric cancer 47
BRCA2-Related Hereditary Cancer Syndrome-Associated Small Bowel Adenocarcinoma With Multiple BRCA2 Mutations: A Case Report and Review of the Literature 47
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials 46
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer A Subgroup Analysis of the TOSCA Randomized Clinical Trial 46
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy 44
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan 44
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 42
Treatment options for EGFR T790M-negative egfr tyrosine kinase inhibitor-resistant non-small cell lung cancer 42
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases 39
Transient receptor potential ankyrin 1 (TRPA1) mediates reactive oxygen species-induced Ca2+ entry, mitochondrial dysfunction, and caspase-3/7 activation in primary cultures of metastatic colorectal carcinoma cells 38
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 38
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas 37
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 36
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell’Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO) 36
Mucinous cystic neoplasms of the liver: Literature review and case series 35
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 34
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 34
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei 33
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study 31
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study 31
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 31
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial 31
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation 30
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 27
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial 24
Harnessing the gut microbiota in extra-intestinal cancers: from causal evidence to immunotherapy strategies 20
WED-346 Single-cell profiling reveals altered natural killer cell composition and transcriptional programs in MASLD-related HCC 15
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come 14
326P The journey of patients (pts) with biliary tract cancers (BTCs): Identifying challenges and unmet needs 14
WED-248 Circulating miRNAs as predictive biomarkers of response to immunotherapy in hepatocellular carcinoma (HCC) 13
FRI-225 Durvalumab–Tremelimumab in advanced hepatocellular carcinoma: real-world data From the LOR-HCC (Lombardy, Italy real-world HCC group) 12
Neoadjuvant immunotherapy in resectable hepatocellular carcinoma: A meta-analysis of the current evidence 9
Prognostic role of metastatic sites in a worldwide population of patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab 8
Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment: The CARACAS study 8
Obstructive sleep apnea as a modifier of endocrine toxicities associated with immune checkpoint inhibitors in lung cancer 8
Thyroid toxicity in lung cancer patients treated with immune-checkpoint inhibitors: a single-center retrospective analysis 7
Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment 6
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real‐World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab 6
Nutritional Support via Jejunostomy Placed During Staging Laparoscopy for Esophagogastric Cancer: A Case Series 6
Multimodal treatment of pineal metastasis from oesophageal adenocarcinoma 5
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 4
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study 4
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 4
Real-life effectiveness of FLOT in resectable gastric cancer: existing challenges 3
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab 3
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 3
Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity? 3
Immune cell changes following chemotherapy in advanced pancreatic cancer with variations based on gender. 3
Interlesional genomic heterogeneity in small bowel adenocarcinoma: evidence from matched primary and peritoneal metastatic lesions 3
Anti-EGFR plus chemotherapy vs. chemotherapy alone in RAS wild-type colorectal liver metastases: A meta-analysis of survival outcomes in resectable and unresectable settings 3
Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts 3
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study 2
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 2
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 2
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis 2
Shedding light in the dark: a sentiment analysis of lymphadenectomy in hilar vs. intrahepatic cholangiocarcinoma 2
null 2
Durvalumab–Tremelimumab in Advanced HepatocellularCarcinoma: Real-World Data From the LOR-HCC(Lombardy Real-World HCC Group) 2
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 1
Navigating the evidence for hepatocellular carcinoma treatment: Surgery vs radiofrequency ablation through sentiment and meta-analysis 1
Totale 3.943
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202422 12 1 2 0 1 0 2 2 0 1 1 0
2024/2025866 1 1 29 2 51 61 100 47 217 61 90 206
2025/20262.687 163 145 150 321 276 122 346 102 273 239 352 198
2026/2027368 175 193 0 0 0 0 0 0 0 0 0 0
Totale 3.943